Autopsy report · NCT02484261

Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children

“Contractual/Funding/Accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month after it had already started.
• 10 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Reuven Schore

Sponsor type

University, hospital or other

Conditions

Leukemia

Interventions

Bortezomib; Pravastatin

Participants

10

Sites

1

Countries

United States

Trials that died the same way

• Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
  “Low Accrual, Funding” (69% match in meaning)
• Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
  “Decision by funding sponsor due to poor accrual” (62% match in meaning)
• Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy
  “Slow accrual and funding limitations.” (62% match in meaning)
• Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
  “Limited funding, slow accrual” (62% match in meaning)
• Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Therapy
  “funding issues and poor accrual” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.